牛牛AI助理已提取核心訊息
Christine E. Thomas, SVP of Regulatory & Clinical at Femasys Inc. (FEMY.US), was reported to have engaged in a transaction involving the company's stock on February 1, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the insider activity within Femasys and its potential impact on the stock's performance.
Christine E. Thomas, SVP of Regulatory & Clinical at Femasys Inc. (FEMY.US), was reported to have engaged in a transaction involving the company's stock on February 1, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the insider activity within Femasys and its potential impact on the stock's performance.
據報道，Femasys Inc.（FEMY.US）監管與臨床高級副總裁克里斯汀·托馬斯於2024年2月1日參與了一項涉及該公司股票的交易。公告中未披露交易的具體細節，包括行動類型、狀態、所涉股票數量、股票性質、交易價格和交易後持有量。這些信息對於投資者了解Femasys內部活動及其對股票表現的潛在影響至關重要。
據報道，Femasys Inc.（FEMY.US）監管與臨床高級副總裁克里斯汀·托馬斯於2024年2月1日參與了一項涉及該公司股票的交易。公告中未披露交易的具體細節，包括行動類型、狀態、所涉股票數量、股票性質、交易價格和交易後持有量。這些信息對於投資者了解Femasys內部活動及其對股票表現的潛在影響至關重要。
有用
沒用